IDO1 Tryptophan Pathway Inhibitors — PatSnap Eureka
IDO1 & Tryptophan Pathway Inhibitor Pipeline: Lessons Learned & Next-Generation Combinations
The kynurenine pathway remains one of oncology's most contested immune checkpoints. After epacadostat's phase III failure, dual IDO1/TDO2 inhibition, PROTAC degraders, and CAR-T combinations are redefining the next generation of tryptophan pathway therapeutics.
IDO1, IDO2 & TDO2: A Multifactorial Immune Checkpoint Axis
IDO1, IDO2, and tryptophan 2,3-dioxygenase (TDO2) are the three cytosolic rate-limiting enzymes catalyzing the first step of tryptophan (Trp) catabolism to kynurenine (Kyn) along the kynurenine pathway. All three are highlighted as clinically relevant targets across more than a dozen retrieved literature records. IDO1 overexpression is broadly associated with reduced tumor-infiltrating immune cells, increased regulatory T cell (Treg) infiltration, and poor prognosis across multiple solid tumor types.
The immunosuppressive cascade downstream of IDO1 activation is multifactorial. Tryptophan depletion activates the GCN2 kinase — an integrated stress response sensor of uncharged tRNA — suppressing effector T cell function and promoting Treg differentiation. Critically, one paper from New Link Genetics also identifies inhibition of mTOR and PKC-Θ and induction of autophagy as additional IDO-dependent immunosuppressive outputs not fully explained by GCN2 activation alone, indicating the IDO pathway operates via multiple downstream effectors simultaneously.
A University of Auckland analysis highlights that tryptophan itself may function as a "rheostat" of kynurenine-mediated immunosuppression by competing with kynurenine for T cell entry — a mechanistic nuance beyond simple enzyme inhibition. The German Cancer Research Center (DKFZ) identifies the aryl hydrocarbon receptor (AhR) as the major downstream receptor for kynurenine and kynurenic acid, expanding the druggable space beyond direct enzyme inhibition to "multiple levels" of the pathway.
IDO2 — a paralog with markedly lower catalytic efficiency than IDO1 — may represent an alternative immunotherapy target, particularly in IDO1-independent immunosuppressive contexts. TDO2, expressed primarily in the liver but also in tumors, can sustain kynurenine production when IDO1 is inhibited, providing a critical bypass resistance mechanism that may explain translational failures. Explore the full landscape using PatSnap's IP analytics platform.
Five Distinct Approaches to Targeting the Tryptophan Pathway
From first-generation small-molecule inhibitors to PROTAC degraders and CAR-T combinations, the IDO1 field has diversified significantly beyond catalytic enzyme blockade.
Small-Molecule IDO1 Enzymatic Inhibitors
The dominant modality across retrieved results, encompassing at least 10 papers and 2 patents. These compounds directly inhibit IDO1 heme-dependent dioxygenase activity, blocking the rate-limiting conversion of Trp to Kyn. Multiple binding subsites (pockets A, B, and C) within the IDO1 active site are engaged differentially by different scaffold classes. A key EPFL finding: a "dramatic drop in activity upon extension to pocket B" for diverse haem-binding inhibitor scaffolds. Epacadostat (Incyte) reached phase III before yielding a negative primary endpoint. Novel scaffolds include EPFL's triazole series with best compound IC50 of 34 nM (both enzymatic and cellular), and Henan Normal University's icotinib-linked triazole a17 at IC50 = 0.37 μM.
10+ papers & 2 patents · Preclinical (novel scaffolds)Dual IDO1/TDO2 Inhibitors
TDO2 expressed in tumors can sustain kynurenine production when IDO1 alone is inhibited, providing a bypass mechanism that may explain clinical failures. Dual inhibition strategies address this directly. STB-C017, discovered via deep learning by Cha University, demonstrated oral bioavailability, suppression of Kyn in plasma and tumor in vivo, increased CD8+ T cell infiltration, and reprogramming of the tumor microenvironment immune gene expression as monotherapy. Peking University holds an active European patent for aza-tryptanthrin derivatives as IDO1/TDO dual inhibitors with stated utility in tumors, autoimmune disease, infectious disease, Alzheimer's disease, and depression.
EP patent active (Peking Univ.) · PreclinicalIDO1 PROTAC Degraders
Proteolysis-targeting chimera (PROTAC) technology has been successfully applied to IDO1 degrader development, representing a modality distinct from catalytic inhibition. The rationale: IDO1 may exert non-enzymatic scaffold functions relevant to immune signaling, which would not be addressed by catalytic inhibitors but would be eliminated by targeted protein degradation. Identified in a 2021 review from Zhengzhou University as a "novel therapeutic" direction, PROTAC-based IDO1 elimination could address residual immunosuppression left intact by conventional small-molecule inhibitors.
Zhengzhou University · Discovery stageIDO1-Targeted Peptide Vaccines
Peptide vaccine approaches that stimulate immune recognition of IDO1-expressing cells are being assessed in clinical trials alongside small-molecule inhibitors, as noted in 2021 and 2022 reviews from Zhengzhou University and Sichuan Provincial People's Hospital respectively. No clinical outcome data from these trials are available in the retrieved dataset. This modality represents a distinct immunological strategy — targeting the IDO1-expressing cell rather than the enzyme's catalytic function — with a different safety and combination potential profile from small-molecule inhibitors.
Clinical stage · Outcome data pendingIDO1 Pipeline by the Numbers
Key quantitative signals from patent and literature analysis of the tryptophan-kynurenine pathway inhibitor field.
Novel IDO1 Inhibitor Scaffold Potency (IC50)
EPFL's haem-binding triazole series leads with a best compound IC50 of 34 nM; Henan Normal University's icotinib-linked triazole a17 achieves 370 nM.
IDO1 Pipeline: Modality Distribution
Small-molecule enzymatic inhibitors dominate the retrieved dataset (10+ papers & 2 patents), with dual IDO1/TDO2, PROTAC, vaccine, and CAR-T approaches emerging.
Key IDO1 Clinical Development Timeline
From the first NLG919 phase I trial (NCT02048709, 2014) through epacadostat's phase III failure (ECHO-301/KN-252) and the post-failure reassessment era.
Six Combinatorial Frameworks for the Post-Epacadostat Era
Retrieved results signal distinct combinatorial frameworks that move beyond the failed IDO1 + anti-PD-1 paradigm, addressing the mechanistic gaps that contributed to ECHO-301's negative primary endpoint.
IDO1 + PD-1/PD-L1: Reassessed, Not Abandoned
The standard combination failed in phase III, but the Brussels group argues it remains viable with more sophisticated patient stratification, different IDO1 inhibitor pharmacological profiles, and biomarker-driven patient selection. Pharmacokinetic inadequacy of tumor drug distribution and TDO2-mediated bypass are cited as correctable failure modes — not fundamental target invalidation.
Dual IDO1/TDO2 Inhibition
Signals from Cha University (deep-learning-derived STB-C017), IOmet Pharma, and the Peking University EP patent converge on dual enzyme inhibition as the strategy to eliminate TDO2 bypass resistance. STB-C017 demonstrated in vivo TME reprogramming as monotherapy, suggesting dual inhibition may generate efficacy signals even without checkpoint inhibitor combination.
CAR-T + Kynurenine Pathway Modulation
Juno Therapeutics' active EP patent (2022) covers both pharmacological and cell-engineering approaches to kynurenine pathway circumvention in adoptive cell therapy — engineering T cells to resist IDO1-mediated immunosuppression intrinsically. This positions the combination in the adoptive cell therapy framework rather than the checkpoint inhibitor framework, with distinct IP implications.
Downstream AhR Pathway Targeting
The DKTK/German Cancer Research Center identifies AhR as a targetable downstream effector, opening the possibility of combining upstream Trp pathway enzyme inhibitors with AhR antagonists, or bypassing IDO1/TDO2 entirely by targeting AhR directly. The Explicyte review (2022) reinforces AhR activation by kynurenine as a major immunosuppression driver "in numerous types of cancer."
Key Commercial and Academic Players in the IDO1 Field
Innovation activity is distributed between commercial patent holders and academic research groups, with a clear predominance of academic literature. Chinese academic institutions and European biotechs are notably active in medicinal chemistry campaigns.
| Organisation | Country | Activity Type | Stage | Key Contribution |
|---|---|---|---|---|
| Incyte Corporation | USA (Wilmington, DE) | Commercial / Patent | Phase III | Originator of epacadostat (INCB24360); most clinically advanced IDO1 inhibitor in this dataset |
| Juno Therapeutics | USA | Commercial / Patent | EP Patent Active | Active EP patent (2022) covering CAR-T/kynurenine pathway modulator combination therapy |
| Peking University | China | Academic / Patent | EP Patent Active | Aza-tryptanthrin derivatives as IDO1/TDO dual inhibitors; multi-indication claims including Alzheimer's |
| EPFL (Lausanne) | Switzerland | Academic / Literature | Preclinical | Structure-based type III IDO1 inhibitor optimization; best compound IC50 = 34 nM (enzymatic & cellular) |
| Cha University | South Korea | Academic / Literature | Preclinical | Deep learning discovery of STB-C017; dual IDO/TDO inhibitor with in vivo TME reprogramming |
| University of Auckland | New Zealand | Academic / Literature | Preclinical Tools | Tryptophan rheostat model; engineered LLC cell lines for isoenzyme selectivity profiling |
Track Every IDO1 Patent Filing and Assignee Move
PatSnap Eureka monitors new filings, status changes, and competitive intelligence across the full tryptophan pathway IP landscape. Explore the customer case studies to see how R&D teams use Eureka for competitive IP tracking.
What the IDO1 Field Has Learned — and Where It Goes Next
Retrieved results across multiple groups converge on four key strategic insights for drug developers, IP strategists, and R&D decision-makers in the tryptophan pathway space.
Phase III Failure ≠ Target Invalidation
Clinical failure of IDO1 monotherapy and IDO1 + anti-PD-1 combinations does not invalidate the biological target. Retrieved results across multiple groups converge on the view that epacadostat's phase III failure reflects limitations in trial design, patient selection, pharmacokinetics, and the presence of IDO1-independent Kyn production via TDO2 — not a fundamental invalidation of the kynurenine pathway as a therapeutic axis. Dual IDO1/TDO2 inhibitors and downstream AhR antagonists represent the most mechanistically coherent next-generation responses. Access the PatSnap life sciences intelligence platform to monitor emerging clinical signals.
Multiple groups · Consensus viewPROTAC Degradation Offers Non-Enzymatic Coverage
If IDO1 exerts non-enzymatic scaffold or signaling functions contributing to immune suppression, catalytic inhibitors would leave these intact. PROTAC-based IDO1 elimination — identified in this dataset as an emerging direction — could address this gap and warrants IP and scientific investment. This is particularly relevant given that conventional small-molecule inhibitors may achieve full enzymatic blockade yet leave scaffold-mediated immunosuppression intact, potentially explaining residual immune evasion in treated tumors. The PatSnap API enables programmatic monitoring of emerging PROTAC patent filings.
Zhengzhou University · 2021 reviewTumor PK Is an Underappreciated Go/No-Go Criterion
Comparative pharmacological data from Yantai University (PCC0208009 vs. INCB024360 vs. NLG919) indicate that equivalent in vitro potency does not predict equivalent in vivo Kyn/Trp suppression, with tumor distribution being a critical differentiator. PCC0208009 outperformed both epacadostat and NLG919 in tumor distribution and in vivo Kyn/Trp modulation in CT26 and B16F10 mouse models. Drug developers should incorporate tumor distribution pharmacokinetics as a go/no-go criterion earlier in candidate selection — a lesson directly applicable to next-generation IDO1 scaffold programs.
Yantai University · 2020CAR-T + Metabolic Checkpoint Space Is Being Patented Now
Juno Therapeutics' active EP patent (2022) covering both pharmacological and cell-engineering approaches to kynurenine pathway circumvention in adoptive cell therapy represents a significant IP claim that may define freedom-to-operate constraints for competitors entering the CAR-T/metabolic checkpoint combination space. Developers whose IDO1 assets have failed in oncology may also find differentiated clinical paths in depression, Alzheimer's disease, or autoimmune disease, where the immunosuppressive function of the kynurenine pathway has distinct and not yet clinically tested relevance. Review PatSnap's trust and compliance framework for enterprise IP monitoring.
Juno Therapeutics EP 2022 · ActiveIDO1 & Tryptophan Pathway Inhibitors — key questions answered
The ECHO-301/KN-252 phase III study in metastatic melanoma produced a negative primary endpoint. Possible explanations discussed in the literature include lack of patient selection biomarkers, pharmacokinetic inadequacy of tumor drug distribution, redundancy of immunosuppressive pathways, and TDO2-mediated bypass of IDO1 inhibition. The Brussels group suggests that combination with checkpoint blockade remains viable but requires more sophisticated patient stratification and possibly different IDO1 inhibitor pharmacological profiles.
IDO1, IDO2, and tryptophan 2,3-dioxygenase (TDO2) are the three cytosolic rate-limiting enzymes catalyzing the first step of tryptophan catabolism to kynurenine along the kynurenine pathway. IDO2 is a paralog with markedly lower catalytic efficiency than IDO1, but may represent an alternative immunotherapy target particularly in IDO1-independent immunosuppressive contexts. TDO2 is expressed primarily in the liver but also in tumors, and can sustain kynurenine production when IDO1 is inhibited, providing a bypass resistance mechanism.
Dual IDO1/TDO2 inhibitors simultaneously block both IDO1 and TDO2 enzymes to eliminate the TDO2 bypass resistance mechanism that undermines IDO1-selective inhibitors. TDO2, expressed in tumors, can sustain kynurenine production when IDO1 alone is inhibited. Key examples include STB-C017, a novel dual IDO/TDO inhibitor discovered via deep learning that demonstrated oral bioavailability, suppression of Kyn in plasma and tumor in vivo, increased CD8+ T cell infiltration, and reprogramming of the tumor microenvironment immune gene expression.
The aryl hydrocarbon receptor (AhR) is the major downstream receptor for kynurenine and kynurenic acid. AhR activation drives immunosuppression and is increasingly recognized as a co-target in the kynurenine pathway. Retrieved data suggest that AhR blockade could complement or even substitute for upstream enzyme inhibition, and that understanding AhR-dependent transcriptional programs expands therapeutic opportunities to multiple levels of the pathway.
A PROTAC (proteolysis-targeting chimera) IDO1 degrader eliminates the IDO1 protein entirely rather than simply blocking its catalytic activity. The rationale is that IDO1 may exert non-enzymatic scaffold functions relevant to immune signaling, which would not be addressed by catalytic inhibitors but would be eliminated by targeted protein degradation. This is presented as a novel therapeutic direction distinct from conventional small-molecule enzyme inhibition.
Yes. The Peking University EP patent explicitly lists Alzheimer's disease, depression, anxiety, autoimmune disease, and infectious disease as target indications for IDO1/TDO dual inhibitors. Mechanistic literature on mTOR/GCN2/AhR downstream biology also supports the rationale for IDO1/TDO inhibitor programs in neurological and autoimmune indications, where the immunosuppressive function of the kynurenine pathway has distinct and not yet clinically tested relevance.
Still have questions about the IDO1 pipeline? Let PatSnap Eureka answer them instantly.
Ask Eureka About IDO1 InhibitorsAccelerate Your Tryptophan Pathway Drug Discovery with AI-Powered Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to navigate complex pipeline landscapes, identify white space, and monitor competitive IP in real time.
References
- Targeting Tryptophan Catabolism in Cancer Immunotherapy Era: Challenges and Perspectives — Explicyte, Bordeaux, France, 2022
- Current Challenges for IDO2 as Target in Cancer Immunotherapy — University of Perugia, Italy, 2021
- Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy — Zhengzhou University, China, 2021
- Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges — Sichuan Provincial People's Hospital, 2022
- Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators [Patent] — Juno Therapeutics, Inc., EP, 2022
- Is There a Clinical Future for IDO1 Inhibitors After the Failure of Epacadostat in Melanoma? — King Albert II Cancer Institute, Brussels, 2020
- INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology — Incyte Corporation, 2017
- Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO — University of Auckland, New Zealand, 2021
- Evaluation of Novel Inhibitors of Tryptophan Dioxygenases for Enzyme and Species Selectivity Using Engineered Tumour Cell Lines — University of Auckland, New Zealand, 2022
- IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan — New Link Genetics Corporation, 2012
- Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors — German Cancer Research Center (DKFZ), Heidelberg, 2015
- The therapeutic potential of targeting tryptophan catabolism in cancer — Heidelberg University, Germany, 2019
- Aza-tryptanthrin derivatives as IDO1 and/or TDO inhibitors [Patent] — Peking University, EP, 2022
- Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway — Cha University, 2021
- Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold — University of Ljubljana, Slovenia, 2021
- Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors — EPFL, Lausanne, 2022
- Synthesis, Docking and Biological Evaluation of a Novel Class of Imidazothiazoles as IDO1 Inhibitors — University of Piemonte Orientale, Italy, 2019
- Discovery of natural products as novel indoleamine 2,3-dioxygenase 1 inhibitors through high-throughput screening — Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 2019
- Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects — Yantai University, China, 2020
- Targeting the IDO1 pathway in cancer: from bench to bedside — 2019
- Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment — Rostock University Medical Center, Germany, 2019
- A Phase I study of NLG919 for adult patients with recurrent advanced solid tumors — Georgia Regents University, 2014
- Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening — China Pharmaceutical University, 2019
- Identification and optimisation of next generation inhibitors of IDO1 and TDO — IOmet Pharma Ltd, Edinburgh, UK, 2015
- Preclinical assessment of a novel small molecule inhibitor of indoleamine 2,3-dioxygenase 1 (IDO1) — iTeos Therapeutics, Gosselies, Belgium, 2014
- National Center for Biotechnology Information (NCBI) — TDO2 Gene Reference — NCBI, NIH
- German Cancer Research Center (DKFZ) — Cancer Immunotherapy Research — DKFZ, Heidelberg
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only — it should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.